In conclusion, we have identified two PLK1 inhibitors, BI2536 and volasertib, and the DNA synthesis inhibitor gemcitabine as highly effective against MPNST cells, while being tolerable to normal HSC cells and bone marrow cells, and we propose these drugs as good candidates for future clinical testing, alone or in combination. The gene discussed is PLK1; the disease is malignant peripheral nerve sheath tumor.